about
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of originA genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Glenda G Anderson
@en
Glenda G Anderson
@nl
type
label
Glenda G Anderson
@en
Glenda G Anderson
@nl
prefLabel
Glenda G Anderson
@en
Glenda G Anderson
@nl
P31
P496
0000-0002-9205-2021